Dyadic International, Inc.
DYAI
Price:
$1.26
Market Cap:
$37.14M
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validat...[Read more]
Industry
Biotechnology
IPO Date
2008-01-16
Stock Exchange
NASDAQ
Ticker
DYAI
The ROE as of September 2024 (TTM) for Dyadic International, Inc. (DYAI) is -145.95%
According to Dyadic International, Inc.’s latest financial reports and current stock price. The company's current ROE is -145.95%. This represents a change of 252.98% compared to the average of -41.35% of the last 4 quarters.
Dyadic International, Inc. (DYAI) Historical ROE (quarterly & annually)
How has DYAI ROE performed in the past?
The mean historical ROE of Dyadic International, Inc. over the last ten years is 0.29%. The current -145.95% ROE has changed -49747.27% with respect to the historical average. Over the past ten years (40 quarters), DYAI's ROE was at its highest in in the September 2014 quarter at 117.48%. The ROE was at its lowest in in the September 2015 quarter at -303.09%.
Average
0.29%
Median
-18.29%
Minimum
-115.60%
Maximum
264.05%
Dyadic International, Inc. (DYAI) ROE by Quarter and Year
Discovering the peaks and valleys of Dyadic International, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 213.72%
Maximum Annual ROE = 264.05%
Minimum Annual Increase = -1684.25%
Minimum Annual ROE = -115.60%
| Year | ROE | Change |
|---|---|---|
| 2023 | -115.60% | 36.78% |
| 2022 | -84.52% | 20.29% |
| 2021 | -70.26% | 114.34% |
| 2020 | -32.78% | 41.51% |
| 2019 | -23.16% | 72.77% |
| 2018 | -13.41% | 213.72% |
| 2017 | -4.27% | -31.68% |
| 2016 | -6.26% | -107.02% |
| 2015 | 89.15% | -66.24% |
| 2014 | 264.05% | -1684.25% |
Dyadic International, Inc. (DYAI) Average ROE
How has DYAI ROE performed in the past?
The current ROE of Dyadic International, Inc. (DYAI) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-90.13%
5-year avg
-65.26%
10-year avg
0.29%
Dyadic International, Inc. (DYAI) ROE vs. Peers
How is DYAI’s ROE compared to its peers?
Dyadic International, Inc.’s ROE is greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Decibel Therapeutics, Inc. (-84.03%), greater than Celcuity Inc. (-60.83%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-385.90%), greater than Molecular Partners AG (-33.08%), greater than MediciNova, Inc. (-13.37%), less than Champions Oncology, Inc. (1.48%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Forte Biosciences, Inc. (-117.85%), greater than DiaMedica Therapeutics Inc. (-38.56%), less than Kineta, Inc. (934.78%), greater than Kintara Therapeutics, Inc. (-836.30%),
| Company | ROE | Market cap |
|---|---|---|
| -48.25% | $88.28M | |
| -28.01% | $1.64B | |
| -84.03% | $123.37M | |
| -60.83% | $557.67M | |
| -44.60% | $374.42M | |
| -122.97% | $46.68M | |
| -21.96% | $77.28M | |
| -54.72% | $30.44M | |
| -47.03% | $495.57M | |
| -385.90% | $26.62M | |
| -33.08% | $182.90M | |
| -13.37% | $103.00M | |
| 1.48% | $57.77M | |
| -23.13% | $108.71M | |
| -117.85% | $11.11M | |
| -38.56% | $172.27M | |
| 934.78% | $8.08M | |
| -836.30% | $9.63M |
Build a custom stock screener for Dyadic International, Inc. (DYAI) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyadic International, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Dyadic International, Inc. (DYAI) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Dyadic International, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Dyadic International, Inc.'s ROE?
How is the ROE calculated for Dyadic International, Inc. (DYAI)?
What is the highest ROE for Dyadic International, Inc. (DYAI)?
What is the 3-year average ROE for Dyadic International, Inc. (DYAI)?
What is the 5-year average ROE for Dyadic International, Inc. (DYAI)?
How does the current ROE for Dyadic International, Inc. (DYAI) compare to its historical average?